Corporate
CGS Administrators, LLC

Serving the states of MN, WI, IL, IN, OH, KY and MI

March 1, 2019

Tumor Treatment Field Therapy Contractor Advisory Committee Key Questions

For each Key Question, please use the following scale identifying your level of confidence with a score of 1 being low or no confidence and 5 representing high confidence.

1
Low Confidence
2 3
Intermediate
4 5
High Confidence

For all questions posed below, the term "newly diagnosed glioblastoma multiforme" and the use of Tumor Treatment Fields Therapy refers to patients who receive Tumor Treatment Field Therapy (TTFT) as an adjuvant modality following initial treatment with debulking surgery or biopsy, followed by chemoradiation with concomitant temozolomide and radiotherapy.

1. How confident are you that there is sufficient evidence to determine that TTFT for newly diagnosed GBM can provide net positive health outcomes in the Medicare-eligible population?
1
Low Confidence
2 3
Intermediate
4 5
High Confidence
2. How confident are you that the available evidence demonstrates adequate predictors of success in Medicare-eligible population?
1
Low Confidence
2 3
Intermediate
4 5
High Confidence
3. How confident are you that TTFT is generally accepted by the medical community for newly diagnosed GBM?
1
Low Confidence
2 3
Intermediate
4 5
High Confidence
4. How confident are you that scientific evidence supports mitotic spindle disruption and cellular apoptosis as the mechanism of action of TTFT?
1
Low Confidence
2 3
Intermediate
4 5
High Confidence
5. How confident are you that there are no significant evidence gaps that may impact positive health outcomes in the Medicare-eligible population?
1
Low Confidence
2 3
Intermediate
4 5
High Confidence
Two Vantage Way, Nashville, TN 37228 © CGS Administrators, LLC. All Rights Reserved